Endpoints

Related by string. endpoint * * Secondary endpoints include . primary efficacy endpoint . secondary efficacy endpoints . video conferencing endpoints . Secondary endpoints included . primary efficacy endpoints . primary endpoint . secondary endpoints . primary endpoints . secondary endpoint . Symantec Endpoint Protection . Secondary endpoints . efficacy endpoints *

Related by context. Frequent words. (Click for all words.) 65 endpoints 60 Heart Failure Patients 59 Secondary endpoints 58 Monotherapy 58 Meta Analysis 58 Thrombolysis 58 Significantly Reduces 58 Elderly Patients 57 endpoint 57 Lesion 57 secondary efficacy endpoints 57 Postmenopausal Women 57 secondary endpoints 57 Phase III Trial 57 Tolerability 56 Solid Tumors 56 Overactive Bladder 56 C Reactive Protein 56 Pharmacokinetic 56 Patients Treated 56 Combination Therapy 56 Study Demonstrates 55 Acute Myocardial Infarction 55 Immunogenicity 55 Efficacy 55 Lenalidomide 55 Pioglitazone 55 Bevacizumab 55 Percutaneous Coronary Intervention 55 Low Dose 54 PRECISE 54 Clinical Trial Results 54 Clinical Outcomes 54 Pivotal Phase 54 Phase III Clinical Trial 54 Pivotal Trial 54 Drug Eluting Stents 54 Secondary endpoints included 54 Ischemic 54 secondary endpoint 54 SABCS 53 Anticoagulation 53 Pivotal Phase III 53 Benign Prostatic Hyperplasia 53 Drug Candidate 53 Clopidogrel 53 Advanced Prostate Cancer 53 Stenting 53 Carotid 53 FDA Clears 53 Infliximab 53 Chronic Hepatitis C 53 Preclinical Data 53 patients evaluable 53 Pulmonary Arterial Hypertension 52 efficacy endpoints 52 Prognostic 52 Non Invasive 52 primary endpoints 52 Multicenter 52 mycophenolate mofetil 52 Natalizumab 52 Metastatic Melanoma 52 prespecified 52 Randomized Controlled Trial 52 Main Outcome Measures 51 mucosal healing 51 lacosamide 51 tipranavir 51 Prophylaxis 51 Secondary endpoints include 51 TAXUS Stent 51 Induces 51 Drug Eluting Stent 51 Completes Enrollment 50 active comparator 50 evaluable 50 Cost Effectiveness 50 dose regimens 50 surrogate endpoint 50 mg BID 50 pharmacodynamic effects 50 composite endpoint 50 Myocardial 50 prospective randomized controlled 50 Fidaxomicin 50 TRITON TIMI 50 primary efficacy endpoints 50 Disease Activity 50 Enoxaparin 50 Dyslipidemia 50 Correlates 50 COPAXONE R 50 FOLFIRI 49 primary endpoint 49 SCH # 49 Gemcitabine 49 irbesartan 49 SPIRIT III 49 Traficet EN 49 randomized controlled clinical trials

Back to home page